Ben is Xconomy's Deputy Biotechnology Editor. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
For three years, a group of investors and experienced neuroscience executives have been stealthily advancing one of the more ambitious new startups in neurology, called BlackThorn Therapeutics. Today they’re finally shedding... Read more »
Five years is a long time. But in New York biotech it might as well be a century given how fast things are changing.
Back in 2011, Xconomy held an event... Read more »
Five years ago, in November 2011, a company from Princeton, NJ, called Pharmasset shared news that would have an impact on millions of people around the world with hepatitis C. Its... Read more »
Celgene late Sunday provided more details on one of the more important drugs in its pipeline, a pill the Summit, NJ, company is developing for inflammatory bowel disease. Analysts on Wall... Read more »
Regeneron Pharmaceuticals has seen its share of ups and downs over the years developing a drug for chronic pain that could represent an alternative to addictive opioids. And another roadblock just... Read more »
For close to a decade, Tom Daniel and George Golumbeski comprised perhaps one of the best-known dealmaking duos in biopharma, striking a slew of alliances that established Summit, NJ-based Celgene as... Read more »
On Aug. 4, shares of Bristol-Myers Squibb closed at $75.32. Today, shares are worth just over $50. That means in three months, Bristol has lost a third of its value, equivalent... Read more »
After flying high for a few years, Bluebird Bio has dealt with some adversity. Limitations emerged late last year for a gene therapy the company was developing for the blood diseases... Read more »
The European Society for Medical Oncology’s annual conference wraps up in Copenhagen today. We’ve seen updates on heavyweight immunotherapy programs, potential options for patients with advanced breast cancer, and more. Here’s... Read more »
A few weeks ago, Xconomy spoke with analysts and patient advocates who considered it unlikely that insurers would balk at a potential price of $300,000 a year for eteplirsen (Exondys 51),... Read more »
Earlier this year, Intellia Therapeutics became the second drugmaker using the landmark gene editing technology CRISPR-Cas9 to go public, after Editas Medicine. A third, CRISPR Therapeutics, could be on the... Read more »
Alnylam Pharmaceuticals has gone through more than a decade of twists and turns, trying to become the first company to bring an RNA interference drug, a method of “silencing” disease-causing genes,... Read more »
Sarepta Therapeutics recently won the first FDA approval for a Duchenne muscular dystrophy drug, eteplirsen (Exondys 51). But the future for patients with the complex, progressive, fatal genetic disease is likely... Read more »
In the four years since going public, Merrimack Pharmaceuticals has brought its first drug to market, a treatment for pancreatic cancer. But disappointing sales, mounting losses, and a sagging share price... Read more »
Paroxysmal nocturnal hemoglobinuria may be an ultra-rare blood disease, but Alexion Pharmaceuticals makes over $2 billion a year by selling the only approved drug for it, eculizumab (Soliris). Ra Pharmaceuticals is... Read more »
The presidential race captivated millions of TV viewers this week as the first debate took place in Hofstra. But biotech watchers had other races on their mind. Who will be first... Read more »
The first experimental cell-based cancer immunotherapy, known as CAR-T, could soon be submitted to the FDA for approval. But CAR-T therapies have limitations. One of many companies looking to improve them... Read more »
To date, the studies Genocea Biosciences has run have not made clear how much better its experimental genital herpes vaccine is than a placebo at treating patients with the infection. Genocea... Read more »
[Updated 9/29/16, see below] Several promising antipsychotic drugs have made it to late-stage clinical trials only to come up short. Today, you can add an experimental treatment from Intra-Cellular... Read more »
December 15, 2016
© 2007-2016, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.